4/A: Protara Therapeutics VP, Controller Hannah Fry Corrects Beneficial Ownership Report
SEC Filing
Hannah Fry, VP, Controller of Protara Therapeutics, files an amended Form 4 to correct a misreporting of securities beneficially owned following a transaction.
Summary
- Hannah Fry, VP, Controller of Protara Therapeutics, filed an amended Form 4 on March 28, 2025, to correct a previous filing from January 28, 2025.
- The amendment addresses a misreporting of the amount of securities beneficially owned by Fry following a reported transaction.
- The corrected filing indicates that Fry directly owns 36,812 shares of Protara Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is always viewed favorably.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The correction of the beneficial ownership report ensures accurate information for shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of Earliest Transaction |
| 01/28/2025 | Date of Original Filed Form 4 which was amended |
| 03/28/2025 | Date of Amended Form 4 Filing |
Keywords
Form 4, Beneficial Ownership, Protara Therapeutics, TARA, Hannah Fry, Securities, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.